None listed
Conditions
Interventions
Drug : Intervention group: Selenium 100microgram twice a day, vitamin complex once a day for 6 months
Control group: vitamin complex once a day for 6 months
Sponsors
Chung-Ang Univerisity Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients with mild or moderate Graves' ophthalmopathy - Patients diagnosed with mild or moderate Graves' ophthalmopathy by an ophthalmologist - NO SPECS class 2a or 2b patients (conjunctival edema, eyelid edema) - Patients with exophthalmos = 22 mm - Patients who did not have other treatment for Graves' 2 Graves disease patient with normal thyroid function test - Patients with Graves' disease who are on antithyroid medication and whose thyroid function tests are normal for more than 2 months. - Graves' disease was treated with radioactive isotope therapy for patients who had been treated with radioisotope for more than 6 months but whose thyroid function test was normal - Patients with Graves' disease who developed hypothyroidism after treatment of antithyroid drugs, radioisotope therapy, and surgical treatment should be treated with thyroid hormone therapy for at least 6 months before the study, - Patients diagnosed with Graves' ophthalmopathy by an ophthalmologist but who were still before thyrotoxicosis and thyroid receptor antibody positive 3 Those who voluntarily signed the agreement
Exclusion criteria
Exclusion criteria: ? Those who do not voluntarily agree to clinical trials ? Severe Graves ophthalmopathy - Patients with NO SPECS class 2C (soft tissue involvement, orbital edema, etc.) - Patients with exophthalmos> 22 mm - Patients with ocular torticollis when there is diplopia or silence - Patients with visual neuropathy - A severe Graves eye disease when an ophthalmologist judges ? Patients who have received steroid or selenium treatment within the last 3 months ? Patients who fall under the contraindication of drug administration I. Patients who are hypersensitive to the drug or its components II. Selenium toxic patient III. Hereditary fructose intolerance, glucose-galactose uptake disorder or white sugar-isomaltase deficiency ? Others Patients with other serious diseases such as the following I. Patients with heart and circulatory dysfunction - those diagnosed with heart failure, coronary artery disease, arrhythmia, and currently taking medication II. Patients with renal impairment - GFR <60 ml / min III. Patients with hypoproteinemia - Albumin <3.3 g / dL IV. Pregnant or potentially pregnant women V. Maternity VI. Patient receiving medical treatment VII. Patients with gastrointestinal diseases such as peptic ulcer, chronic ulcerative colitis, localized colitis ? Other, if judged by the researcher to be inappropriate for participation in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of quality of life score of thyroid ophthalmopathy | — |
Secondary
| Measure | Time frame |
|---|---|
| Ophthalmological improvement | — |
Countries
Korea, Republic of
Contacts
Public ContactHwa Young Ahn
Chung-Ang University
Outcome results
None listed